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cleavage is functional in assembling the membrane attack complex.
The hypothesis that plasmin can act as a C5 convertase was tested
in an arterial model in which plasminogen was activated by tissueBoth the complement and coagulation/ﬁbrinolytic systems are
essential components of the host defense system that evolved early in
the evolution of vertebrates (Krem and Di Cera, 2002). While the
coagulation and ﬁbrinolytic systems are necessary for maintenance of
the integrity of the vasculature, these systems also respond to infec-
tions, and together with the complement system, play an important
role in innate and adaptive immunity.
There are two pathways in mammals that initiate coagulation and
three that initiate complement while ﬁbrinolysis commences in
response to the presence of a ﬁbrin clot (Bajic et al., 2015; Smith et al.,
2015). The intrinsic or contact pathway for initiation of coagulation
and the alternative (properdin) and lectin pathways that initiate
complement activation are activated by speciﬁc properties of some
surfaces such as bacterial or yeast cell walls.
Cross talk between the various systems is apparent with several
well-described interactions such as that between C4-binding protein
(C4BP) that regulates complement by inhibiting the classical initiation
pathway and protein S, the latter being a cofactor for activated protein
C, a regulator of coagulation and inﬂammation. There are in vitro and
in vivo data that suggest coagulation cascade enzymes such as thrombin
could cleave C5, carrying out the same reactions as the C5 convertase
(Huber-Lang et al., 2006). The cleavage products, however, did not
directly generate C5a (Krisinger et al., 2012).
A new study (Foley et al., 2016) shows in a venous stasis model that
C5a correlates strongly with clot weight implying that pathways initiat-
ed during clot formation lead to C5 cleavage. In contrast, there is a very
weak correlation with thrombin–antithrombin complexes, suggesting
that thrombin is not directly cleaving C5. They then investigated the
ability of thrombin, factor Xa andplasmin to cleave C5bymeasuring for-
mation of C5a by ELISA. Plasmin, the effector enzyme in the ﬁbrinolytic
cascade, was the only enzyme that was able to cleave complement C5 at
a similar rate as the canonical C5 convertase formed from complementm.2016.02.011.
erans Administration Palo Alto
04.
pen access article under the CC BY-Ncomponents. The resultant C5b can assemble into the next stage of the
plasminogen activator (tPA). They found that the levels of C5a were
increased, consistent with plasmin activating C5.
C5 activationwith consequent generation of C5a and themembrane
attack complex is a feature of many diseases such as arthritis, sepsis and
acute lung injury. Deﬁning the extent of plasmin's role in C5 cleavage
outside of its role in thrombotic diseases would clarify if this reaction
is important in other contexts. The possibility of exploiting this mecha-
nism as a therapeutic target would need to be approached carefully
because of the critical role plasmin plays not just in ﬁbrinolysis but
also in tissue repair and inﬂammatory cell migration (Syrovets et al.,
2012).
The idea that plasmin is a bona ﬁde C5 convertase has several impli-
cations for the links between complement and coagulation. Fibrinolysis
occurs after coagulation and therefore, the C5 cleavage products will be
present during clot resolution aswell as clot formation and progression.
However, C5a is a major chemoattractant and activator for neutrophils,
leading to elaboration of procoagulant neutrophil extracellular traps
(NETs) (Youseﬁ et al., 2009). Leukocytes attracted to the thrombus
can contribute to lysis by secretion of plasminogen activators, thus the
precise balance between the prothrombotic and ﬁbrinolytic factors
may depend on the disease setting.
This study focused on the role of plasmin inC5 cleavage in thrombotic
scenarios, but complement plays a key role in eliminating infections. In
some infectious diseases such as Yersinia, ﬁbrinogen deﬁciency leads to
decreased survival while plasminogen deﬁciency increases survival
(Degen et al., 2007). The survival advantage conferred by plasminogen
deﬁciency is effectively eliminated in ﬁbrinogen/plasminogen double
deﬁcient mice. Thus formation of ﬁbrin prevents the spread of the
disease and ﬁbrinolysis promotes it. The Yersinia virulence factor, Pla,
can activate plasminogen and many other bacteria express plasminogen
activators. It will be important to investigate the role of plasmin in acti-
vating the terminal pathway of complement under these circumstances.
Foley et al. (Foley et al., 2016) only consider the forward reactions,
but these cascades are tightly regulated. The rate of plasminogen activa-
tion is closely controlled by the availability of tPA as well as by plasmin-
ogen activator inhibitor-1 while plasmin activity is regulated by alpha-2
antiplasmin. Interestingly, carboxypeptidase B2 (TAFI), which can be ac-
tivated from its zymogen by either thrombin bound on thrombomodulinC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
21L.L. Leung, J. Morser / EBioMedicine 5 (2016) 20–21or by plasmin (Morser et al., 2010), both reduces activation of plasmin-
ogen as well as inactivating C3a and C5a, thereby functioning as a
regulator of both the enzyme cleaving C5 and one of the products, C5a.
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